nc 1

NC1 is a novel highly active allosteric inhibitor of protein tyrosine phosphatase, non-receptor type 22 (PTPN22) which is a lymphoid-specific tyrosine phosphatase (LYP).

UNC1062 is a highly selective tyrosine kinase inhibitor that specifically targets MERTK. This compound effectively suppresses MERTK-mediated downstream signaling, induces apoptosis in cell cultures, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. Notably, UNC1062 demonstrates potent inhibition of MERTK kinase activity, with an IC50 of 1.1 nM and a Morrison Ki of 0.33 nM. It also displays specificity within the TAM family, exhibiting IC50 values of 60 nM for TYRO3 and 85 nM for AXL [1].

NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor with significant affinity for various BRD4 and BRDT isoforms, as demonstrated by its Kd values of 0.095 nM for BRD4-1, 0.32 nM for BRD4-2, 0.29 nM for BRD4-T, 0.089 nM for BRDT-1, 5.5 nM for BRDT-2, and 0.058 nM for BRDT-T. Additionally, NC-III-49-1 exhibits antiproliferative effects and reduces the expression of c-Myc [1].

NC 1100 is a calcium channel antagonist.

NNC 11-1314 is an agonist of muscarinic acetylcholine receptor (mAChR).

NNC 11-1585 is a bioactive chemical.

NNC 112 is a selective dopamine D1 receptor antagonists.

SNC 162 is a potent and selective delta-opioid receptor (DOR, δ-opioid) agonist with an IC50 value of 0.94 nM with analgesic, antidepressant and antiarrhythmic effects.

NNC 11-1607 is a functionally selective agonist of M(1)/M(4) mAChR.

1. Narirutin (Naringenin-7-O-rutinoside) has antiproliferative property. 2. Narirutin has anti-oxidant property. 3. Narirutin has anti-allergic and anti-inflammatory properties , can reduce airway inflammation in ovalbumin (OVA)-sensitized challenged NC Nga mice , a model of allergic eosinophilic airway inflammation.

[Nphe1]Nociceptin(1-13)NH2 is a novel endogenous ligand for the nociceptin orphanin FQ (NC) receptor, acting as a selective and competitive antagonist without any agonist effects. It binds specifically to recombinant nociceptin receptors with high affinity (pKi=8.4) and effectively blocks nociceptin's ability to inhibit cyclic AMP accumulation in CHO cells (pA2=6.0), showcasing potential as an analgesic agent.

JC2-11 is an inhibitory compound for inflammation.JC2-11 inhibits the recruitment domain-containing proteins NLRC 4, atypical in melanoma 2 (AIM 2) and atypical (NC) inflammatory vesicles by disrupting reactive oxygen species (ROS) production and caspase-1 activity.JC2-11 reduces caspase-1 (p20) secretion, gasdermin D (GSDMD) cleavage, IL-1β and lactate dehydrogenase (LDH) activity in inflammatory vesicles. JC2-11 reduced caspase-1 (p20) secretion, gasdermin D (GSDMD) cleavage, IL-1β and lactate dehydrogenase (LDH) release from inflammatory vesicles.

NC-R17, an RSL3-based noncovalent GPX4 degrader implicated in ferroptosis, demonstrates anti-tumor activity and is utilized in the design of noncovalent GPX4-targeted proteolysis targeting chimeras (PROTACs) [1].

Claficapavir (A1752) is a potent nucleocapsid protein (NC) inhibitor that effectively binds the HIV-1 NC with a dissociation constant (Kd) of 20 nM, resulting in the inhibition of its chaperone properties. This specific molecular interaction leads to strong antiviral activity against HIV-1, with an IC50 of approximately 1 μM [1].

PQA-18, an inhibitor of p21-activated kinase 2 (PAK2; IC50 = 10 nM), is derived from Ppc-1 (product number 42352) and exhibits immunosuppressive properties. It inhibits IL-2 production in Jurkat T cells induced by Concanavalin A (product number 14951) with an IC50 of 400 nM. Topically applied at 0.1%, PQA-18 reduces the severity of atopic dermatitis, serum IgE levels, and skin thickness in the NC Nga mouse model. A lower concentration of 0.05% also decreases skin nerve fiber density in NC Nga mice. Additionally, PQA-18 administered at 4 mg kg improves graft survival in a rat small intestine transplantation model.